Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume?
Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
Elevated Lp(a) doesn't just raise #CV risk, it carries a major economic price tag. Data shared by @nishantshahmd.bsky.social at #ACC26 shows the highest Lp(a) group incurs $506/person/year or $253M over 5 years, in indirect costs. The case for early testing is clear. #ASCVD #cvLipids #CardioSky
Featured on the @todayshow.com: @nbcnews.com medical reporter Dr. Akshay Syal discusses @accintouch.bsky.social and @americanheart.bsky.social's new guideline for managing #cvLipids and #Cholesterol.
📺Watch the video: on.today.com/4lFVuVY #JACC
The 2026 ACC/AHA Multisociety #Dyslipidemia Guideline-at-a-Glance offers a visual summary of key updates in CV risk assessment, lipid treatment goals, & #ASCVD risk reduction.
A quick reference for clinicians: https://bit.ly/4rGIMHY
#JACC #ClinicalGuidelines #cvLipids #CardioSky
🆕 ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management & monitoring of individuals w/ dyslipidemias.
Read the full guideline in #JACC: https://bit.ly/4cLB0J0 #cvLipids #ClinicalGuidelines #CardioSky #MedSky
ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke.
Get the details in #JACC: https://bit.ly/4cLB0J0
#ClinicalGuidelines #cvLipids #ASCVD #CardioSky
Among individuals w/ an elevated baseline cardiovascular risk, reducing the intake of saturated fatty acid was associated w/ a lower risk of mortality, nonfatal myocardial infarction and stroke over five years.
Read the journal scan for more: https://bit.ly/452T64u #cvLipids #CardioSky #MedSky
#AHA25: ACC Vice President Roxana Mehran, MD, FACC, shares insights on groundbreaking cardiometabolic therapeutic trials, including highlights from the VESALIUS-CV study.
Get the full details here: https://bit.ly/4oBNohQ
#cvPrev #cvLipids #ACCAnywhere #CardioSky #MedSky
CRISPR-Cas9 ➡️ First-in-Human trial presented at #AHA25 suggests one-time infusion of an investigational CRISPR-Cas9 therapy targeting ANGPTL3 is safe & can reduce both LDL cholesterol & triglycerides.
Read the ACC News Story for more: https://bit.ly/47Nfb7O
#cvLipids #CardioSky #MedSky
A 🆕 ACC Scientific Statement on Inflammation & #CVD highlights new groundbreaking research linking inflammation #ASCVD & provides consensus-based recommendations for evaluation, treatment & prevention reflecting this new era.
Learn more: https://bit.ly/4nUui5w #cvLipids #CardioSky #MedSky #JACC
Young adults with high remnant cholesterol face significantly increased CV risk, even with optimal LDL-C. Findings from a 4.3M nationwide cohort highlight remnant-C as a potent, age-sensitive risk factor needing early preventive strategies. https://bit.ly/46KV4aP
#JACC #ASCVD #cvLipids #ACCIntl
In this pooled analysis of 2 phase 3 clinical trials, obicetrapib treatment was associated with a reduction in coronary events, evident beyond 6 months of treatment. https://bit.ly/47ljrwK
#JACC #ESCCongress #WCCardio #CVD #MACE #cvLipids
Overweight & obesity are common in patients with HeFH and are associated with a greater risk of #ASCVD starting in childhood and regardless of LDL-C level and lipid-lowering medication.
Read more: bit.ly/40IL3b3
#CardioSky #MedSky #cvLipids